Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis

JAMA Internal Medicine

Volumn 174, Issue 9, 2014, Pages 1494-1501

  Bashir, Riyaz ^a   Zack, Chad J ^a   Zhao, Huaqing ^a   Comerota, Anthony J ^b   Bove, Alfred A ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TOLEDO HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGE; AGED; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTICLE; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CATHETER DIRECTED THROMBOLYSIS; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ETHNICITY; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL CHARGE; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; KIDNEY FAILURE; LENGTH OF STAY; LOWER EXTREMITY CAVAL DEEP VEIN THROMBOSIS; LOWER EXTREMITY DEEP VEIN THROMBOSIS; LOWER EXTREMITY PROXIMAL DEEP VEIN THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORTALITY; NEOPLASM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARALYSIS; SENSITIVITY ANALYSIS; SHOCK; URBAN AREA; VENA CAVA FILTER; BLEEDING; CATHETERIZATION; CHEMICALLY INDUCED; COMPARATIVE STUDY; FIBRINOLYTIC THERAPY; LEG; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROPENSITY SCORE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES; VASCULARIZATION; VENOUS THROMBOSIS;

AGED; ANTICOAGULANTS; CATHETERIZATION; COMBINED MODALITY THERAPY; FEMALE; HEMORRHAGE; HOSPITAL CHARGES; HOSPITAL MORTALITY; HUMANS; LEG; LENGTH OF STAY; MALE; MIDDLE AGED; PROPENSITY SCORE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOSIS;

EID: 84907010363     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3415     Document Type: Article

References (44)

1. Goldhaber S. Epidemiology of Pulmonary Embolism and Deep Vein Thrombosis, Haemostasis and Thrombosis. 3rd ed. New York, NY: Churchill Livingstone; 1994:1327-1333.
2. Hirsh J, Hoak J; Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology); American Heart Association. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Circulation. 1996;93(12):2212-2245.
3. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28(3):370-372.
4. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23)(suppl 1):I4-I8.
5. Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23)(suppl 1):I22-I30.
6. Cogo A, Lensing AW, Prandoni P, Hirsh J. Distribution of thrombosis in patients with symptomatic deep vein thrombosis: implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med. 1993;153 (24):2777-2780.
7. Kahn SR, Springmann V, Schulman S, et al. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting: the Recovery Study. Thromb Haemost. 2012;108(3):493-498.
8. Gauci BN, Powell JT, Hunt BJ, et al. The feasibility of catheter-directed thrombolysis for acute deep vein thrombosis: a regional perspective. Phlebology. 2011;26(3):94-101.
9. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1): 19-25.
10. Schulman S, Lindmarker P, HolmströmM, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4(4): 734-742.
11. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82(4): 423-428.
12. Kahn SR, Kearon C, Julian JA, et al; Extended Low-intensity Anticoagulation for Thrombo-embolism (ELATE) Investigators. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost. 2005;3(4):718-723.
13. Kahn SR, Shbaklo H, Lamping DL, et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost. 2008;6(7):1105-1112.
14. Guanella R, Ducruet T, JohriM, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost. 2011;9 (12):2397-2405.
15. Kahn SR, Ducruet T, Lamping DL, et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med. 2005;165(10):1173-1178.
16. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med. 2002;162(10):1144-1148.
17. Watson LI, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2004(4):CD002783.
18. Enden T, Resch S, White C, Wik HS, Kløw NE, Sandset PM. Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. J Thromb Haemost. 2013;11(6): 1032-1042.
19. Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis. Rev Cardiovasc Med. 2002;3 (suppl 2):S61-S67.
20. AbuRahma AF, Perkins SE,Wulu JT, Ng HK. Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. Ann Surg. 2001;233(6): 752-760.
21. Baekgaard N, Broholm R, Just S, Jørgensen M, Jensen LP. Long-term results using catheter-directed thrombolysis in 103 lower limbs with acute iliofemoral venous thrombosis. Eur J Vasc Endovasc Surg. 2010;39(1):112-117.
22. Meissner MH, Gloviczki P, Comerota AJ, et al; Society for Vascular Surgery; American Venous Forum. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2012;55 (5):1449-1462.
23. MewissenMW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. 1999;211(1):39-49.
24. SharifiM, Mehdipour M, Bay C, Smith G, Sharifi J. Endovenous therapy for deep venous thrombosis: the TORPEDO trial. Catheter Cardiovasc Interv. 2010;76(3):316-325.
25. Singh H, Masuda EM. Comparing short-term outcomes of femoral-popliteal and iliofemoral deep venous thrombosis: early lysis and development of reflux. Ann Vasc Surg. 2005;19(1):74-79.
26. Enden T, Haig Y, Kløw NE, et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379(9810):31-38.
27. Kearon C, Akl EA, Comerota AJ, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e419S-e494S.
28. JaffMR, McMurtryMS, Archer SL, et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788-1830.
29. Agency for Healthcare Research and Quality. Overview of the Nationwide Inpatient Sample (NIS): Healthcare Cost and Utilization Project (HCUP) http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed November 26, 2012.
30. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
31. Cohen J. Applied Multiple Regression/ Correlation Analysis for the Behavioral Sciences. Vol 18. Hillsdale, New Jersey: Lawrence Erlbaum Associates, Inc; 1983.
32. Shariff SZ, Cuerden MS, Jain AK, Garg AX. The secret of immortal time bias in epidemiologic studies. J AmSoc Nephrol. 2008;19(5):841-843.
33. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.
34. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis: a randomised clinical trial. Eur J Vasc Endovasc Surg. 2002;24(3):209-214.
35. Comerota AJ. Thrombolysis for deep venous thrombosis. J Vasc Surg. 2012;55(2):607-611.
36. Klein SJ, Gasparis AP, Virvilis D, Ferretti JA, Labropoulos N. Prospective determination of candidates for thrombolysis in patients with acute proximal deep vein thrombosis. J Vasc Surg. 2010;51(4):908-912.
37. Enden T, Kløw NE, Sandvik L, et al; CaVenT study group. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost. 2009;7(8):1268-1275.
38. Zack CJ, Bashir R, Gaughan J, Bove A. The effect of inferior vena cava filter placement on in-hospital outcomes in patients with lower extremity deep vein thrombosis. http://content.onlinejacc.org/article.aspx?articleid=1666271. Accessed June 11, 2014.
39. Sharifi M, Bay C, Skrocki L, Lawson D, Mazdeh S. Role of IVC filters in endovenous therapy for deep venous thrombosis: the FILTER-PEVI (filter implantation to lower thromboembolic risk in percutaneous endovenous intervention) trial. Cardiovasc Intervent Radiol. 2012;35(6):1408-1413.
40. Herrera S, Comerota AJ. Embolization during treatment of deep venous thrombosis: incidence, importance, and prevention. Tech Vasc Interv Radiol. 2011;14(2):58-64.
41. Kölbel T, Lindh M, Holst J, et al. Extensive acute deep vein thrombosis of the iliocaval segment: midterm results of thrombolysis and stent placement. J Vasc IntervRadiol. 2007;18(2):243-250.
42. Schoenman JA, Sutton JP, Elixhauser A, Love D. Understanding and enhancing the value of hospital discharge data. Med Care Res Rev. 2007;64(4): 449-468.
43. White RH, GarciaM, Sadeghi B, et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res. 2010;126(1):61-67.
44. Arcelus JI, Caprini JA, Monreal M, Suárez C, González-Fajardo J. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J Vasc Surg. 2003; 38(5):916-922.